Tranexamic Acid Prophylaxis Investigated to Mitigate Hemoglobin Decline Post-Episiotomy

Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality worldwide. While major PPH often receives significant attention, even moderate blood loss can lead to postpartum anemia, impacting maternal recovery and well-being. Episiotomy, a surgical incision made during vaginal delivery to enlarge the vaginal opening, is a known contributor to blood loss. Current management primarily focuses on active management of the third stage of labor and treating established hemorrhage. Tranexamic acid (TA), an antifibrinolytic agent, works by inhibiting the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots. Its efficacy in reducing blood loss in various surgical settings and established PPH is recognized, prompting investigation into its prophylactic use in specific high-risk scenarios like episiotomy.

This study was designed as a Randomized Controlled Trial (RCT) with a placebo-controlled arm to evaluate the prophylactic use of tranexamic acid following vaginal delivery involving an episiotomy. The objective was to compare the effect of TA treatment on the decline in hemoglobin (Hb) levels against a control group that did not receive TA. While the abstract specifies the study design and primary endpoint, it does not provide details on the specific tranexamic acid dose, route of administration, frequency, duration of treatment, or the total number of participants (n) enrolled in the trial. The primary endpoint was the change in Hb levels, indicating the extent of blood loss.

The provided abstract outlines the study's objective and design but does not present any specific results or findings regarding the efficacy or safety of tranexamic acid in this context. Therefore, no numerical data, p-values, or fold-changes can be reported from this abstract. The study aimed to assess whether prophylactic TA treatment could reduce the decline in Hb levels following vaginal delivery with an episiotomy. Typically, such a trial would measure outcomes such as the mean difference in Hb decline between groups, the incidence of significant Hb drops (e.g., >2 g/dL), the need for blood transfusions, and potential adverse events. Without these results, the impact of tranexamic acid on blood loss and Hb levels in this specific population remains unreported in this abstract.

The abstract explicitly states the study's objective but provides no data on the actual effect of tranexamic acid on hemoglobin decline.